{"ticker": {"uuid": "d1500be7-56db-49a2-b886-c448c69adf8d", "symbol": "BCAB", "name": "Bioatla\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioAtla: BioAtla, Inc. - Reverse Split Option Symbol: BCAB New Symbol: BCAB1", "summary": "This document announces that BioAtla, Inc. (BCAB) has undergone a reverse split, and a new option symbol, BCAB1, has been introduced. The article title and content solely focus on this corporate action.", "url": "https://www.moomoo.com/news/notice/306846774/bioatla-bioatla-inc-reverse-split-option-symbol-bcab-new-symbol", "source_name": "Moomoo", "published_at": "2026-06-27T22:41:09", "published_display": "27 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioAtla, Inc. \u2013 NASDAQ:BCAB", "summary": "The article discusses the enterprise value to revenue forward for BioAtla, Inc. (NASDAQ: BCAB). It appears to be a financial listing or data point from a trading platform, providing a specific value for this financial metric during a particular period.", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:41:43", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB)", "summary": "This article provides an overview of BioAtla, Inc. (NASDAQ: BCAB) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers key metrics such as market capitalization, volatility, net income, and upcoming earnings dates, offering ", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:43", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Bioatla Inc (BCAB), highlighting its current valuation score of 9.98, which ranks 1st in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -0.02, significantly above its recent low. However, key P/B, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T06:11:35", "published_display": "23 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Bioatla Inc (BCAB), detailing its price momentum, support and resistance levels, and indicator and moving average signals. Currently, BCAB has a price momentum score of 7.42, trading between a resistance of $4.23 and support of $3.13,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/technical", "source_name": "TradingKey", "published_at": "2026-06-22T08:09:53", "published_display": "22 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5nZ0pLY3FIc2NuSnEwOUluV0VmTjJ2WWR4b3dNaV9XT3FycmFjbUR0enFzRnBsd2poMTMzU2luSzZGZ1ZnZ2pIcWRaMW1QQlZJb2prcU5ZaHJuVUFWVkhtem03U2t1aGFValY2VGY1dWo?oc=5", "source_name": "TradingKey", "published_at": "2026-06-19T03:35:09+00:00", "published_display": "19 Jun 2026 03:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Bioatla Inc (BCAB) but states that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows the stock's current trading status and market capitalization", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T03:11:37", "published_display": "19 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides an overview of Bioatla Inc.'s (BCAB) dividend and stock split history. It indicates that BCAB has not distributed any dividends over the past five years. However, it lists a significant stock split event planned as a 50-to-1 merger on March 31, 2026.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T02:11:37", "published_display": "19 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Bioatla Inc (BCAB) has an earnings forecast score of 10.00, placing it first in the Biotechnology & Medical Research industry. Analysts predict a strong buy trend with an average price target of $10.00, suggesting a significant upside. The company's recent EPS was -$8.18, with th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:05", "published_display": "18 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla | 4: Statement of changes in beneficial ownership of securities-Officer Sievers Eric", "summary": "This article is a statement of changes in beneficial ownership of securities for BioAtla, specifically concerning an officer named Sievers Eric. It is a regulatory filing indicating modifications in the individual's holdings of company securities.", "url": "https://www.moomoo.com/news/notice/307479501/bioatla-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-06-10T03:09:13", "published_display": "10 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Inc. (BCAB) Q4 2025 Earnings: EPS Beat Driven by Lower Operating Loss, Stock Declines - Consensus Beat Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQQWNZc3BodWFsQVRxN3g5ZlRsdXZtZmdqcFRHRlFIOTlMYmlzZVZFMDd3MUtKMXpyVkRVa05HNkRsMWVaRzNhNVVfMnU3VVlsLV9kTm1YeW5JMGRJU3BZRTJRZ2lFOEtHdVpvQTE2UzRjYmdiZG1BMExkUThLem1DMEl0cFdHLTg4QjN5TGE5bDZjdFpWcGRFU3dsaENZLTJGdS1sMUFIWG52S3NDX3J1Y3JoS205SzZUeWdpdDFwSld3U1h2OGw3RmlJdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes", "summary": "BioAtla, Inc.'s Chief Medical Officer, Eric Sievers, had a total of 494 common shares withheld to cover income tax obligations related to vested restricted stock units. These transactions, occurring on March 11, 2026, and May 31, 2026, were tax-related share withholdings and not ", "url": "https://www.stocktitan.net/sec-filings/BCAB/form-4-bio-atla-inc-insider-trading-activity-058aabfa7c34.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:11:20", "published_display": "05 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (NASDAQ: BCAB) CEO reports routine tax-share withholdings after RSU vesting", "summary": "BioAtla, Inc. CEO Jay M. Short reported routine tax-related share dispositions following the vesting of restricted stock units (RSUs), not open-market sales. A total of 898 common shares were withheld by the company to cover income tax obligations across two dates in March and Ma", "url": "https://www.stocktitan.net/sec-filings/BCAB/form-4-bio-atla-inc-insider-trading-activity-6d41a4db30ee.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:11:19", "published_display": "05 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes", "summary": "BioAtla (NASDAQ: BCAB) Chief Financial Officer Christian Vasquez reported routine tax-withholding transactions concerning restricted stock units, not open-market stock sales. A total of 257 common shares were withheld by the company on two separate dates in 2026 to cover income t", "url": "https://www.stocktitan.net/sec-filings/BCAB/form-4-bio-atla-inc-insider-trading-activity-ded942ecae3f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:11:19", "published_display": "05 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla | DEFA14A: Others", "summary": "This article provides access to the DEFA14A document filed by BioAtla, which is a definitive additional soliciting material.", "url": "https://www.moomoo.com/news/notice/307460437/bioatla-defa14a-others", "source_name": "Moomoo", "published_at": "2026-06-04T15:39:47", "published_display": "04 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote", "summary": "BioAtla (NASDAQ: BCAB) has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held virtually. Shareholders will vote on the election of two Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and a non-binding advisory vo", "url": "https://www.stocktitan.net/sec-filings/BCAB/def-14a-bio-atla-inc-definitive-proxy-statement-1d2071416511.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:39:20", "published_display": "03 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCAB - BioAtla Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of BioAtla Inc. (BCAB) stock, including its latest stock price, financial metrics, analyst ratings, and recent news. It covers key financial data such as market cap, income, sales, and various ratios, alongside insider ownership and ins", "url": "https://finviz.com/stock?t=BCAB", "source_name": "Finviz", "published_at": "2026-06-01T09:10:09", "published_display": "01 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202", "summary": "Context Therapeutics has amended its exclusive license agreement with BioAtla for CT-202, eliminating future milestone and royalty obligations in exchange for an upfront payment of $4.5 million and a final payment of $2.0 million. This amendment grants Context Therapeutics full e", "url": "https://www.sahmcapital.com/news/content/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-20T03:10:23", "published_display": "20 May 2026 03:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal", "summary": "Context Therapeutics has gained full rights to CT-202 following a revised agreement with BioAtla. The article also briefly mentions Unity Software's Q4 financial results, including a 35% revenue increase year-over-year to $609 million and a quarterly loss of 66 cents per share.", "url": "https://www.moomoo.com/news/post/70178805/context-therapeutics-secures-full-rights-to-ct-202-under-revised?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-18T11:39:12", "published_display": "18 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context to pay $6.5M for full CT-202 rights by Aug. 1, 2026", "summary": "Context Therapeutics has amended its license agreement with BioAtla for CT-202, converting it into a fully paid-up, non-terminable license. This agreement eliminates all future CT-202 milestones and royalties for a total of $6.5 million, with $4.5 million upfront and a final $2.0", "url": "https://www.stocktitan.net/news/CNTX/context-therapeutics-enters-into-license-agreement-amendment-with-iw6ozf41iygo.html", "source_name": "Stock Titan", "published_at": "2026-05-18T11:10:08", "published_display": "18 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free", "summary": "Context Therapeutics has entered into an amendment with BioAtla to convert its antibody licenses, including CT-202, into irrevocable, royalty-free, fully paid-up, and non-terminable rights for $6.5 million. This agreement eliminates Context's R&D and reporting obligations, remove", "url": "https://www.tradingview.com/news/tradingview:63bc336a5abd5:0-context-therapeutics-pays-6-5-million-to-make-bioatla-antibody-licenses-perpetual-and-royalty-free/", "source_name": "TradingView", "published_at": "2026-05-18T11:10:08", "published_display": "18 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license", "summary": "Context Therapeutics (CNTX) has amended its license agreement with BioAtla for its CT-202 program, making the license royalty-free, fully paid-up, and non-terminable in exchange for upfront payments totaling $6.5 million. This agreement gives Context full economic rights to CT-20", "url": "https://www.stocktitan.net/sec-filings/CNTX/8-k-context-therapeutics-inc-reports-material-event-d61f0d627f0e.html", "source_name": "Stock Titan", "published_at": "2026-05-18T11:10:08", "published_display": "18 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Number of shareholders of BioAtla, Inc. \u2013 NASDAQ:BCAB", "summary": "This article provides details on the number of shareholders for BioAtla, Inc. (NASDAQ: BCAB). It is presented on a TradingView page, indicating current market status and offering various financial tools and data. The core content focuses on shareholder figures, though the specifi", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAB/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-14T17:40:13", "published_display": "14 May 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TradingKey", "summary": "This page provides an overview of Bioatla Inc (BCAB) stock performance, including its current price, market capitalization, and P/E TTM. The site offers various financial market data, news, analysis tools, and educational resources. It also includes sections for user comments and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/comments", "source_name": "TradingKey", "published_at": "2026-05-11T14:39:52", "published_display": "11 May 2026 14:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioAtla (Nasdaq:BCAB) - Stock Analysis", "summary": "BioAtla (Nasdaq:BCAB) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancer. The company's stock has shown high volatility and significant decline over the past year, with ongoing concerns about cash burn, sharehold", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcab/bioatla", "source_name": "Simply Wall Street", "published_at": "2026-05-06T23:10:05", "published_display": "06 May 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive pay, board and share data detailed in BioAtla (NASDAQ: BCAB) 10-K/A", "summary": "BioAtla, Inc. filed an amended annual report (10-K/A) to include comprehensive details on executive compensation, board structure, and share ownership, which were previously omitted. The filing reflects a 50-for-1 share consolidation effective April 6, 2026, and provides updated ", "url": "https://www.stocktitan.net/sec-filings/BCAB/10-k-a-bio-atla-inc-amends-annual-report-df203fcc748e.html", "source_name": "Stock Titan", "published_at": "2026-04-29T20:40:23", "published_display": "29 Apr 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BioAtla to implement 50-for-1 share consolidation", "summary": "This article announces that BioAtla will implement a 50-for-1 share consolidation. The content details this corporate action.", "url": "https://www.msn.com/en-us/money/companies/bioatla-to-implement-50-for-1-share-consolidation/ar-AA1ZQHj2?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c", "source_name": "MSN", "published_at": "2026-04-25T02:39:43", "published_display": "25 Apr 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BCAB Stock Chart | BIOATLA INC (NASDAQ:BCAB)", "summary": "This article provides a stock chart and real-time financial data for BIOATLA INC (NASDAQ:BCAB). It shows the current stock price, its daily change, and aftermarket activity. The page also lists various financial analysis tools and educational resources available on ChartMill.com.", "url": "https://www.chartmill.com/stock/quote/BCAB/stock-chart", "source_name": "ChartMill", "published_at": "2026-04-18T02:39:23", "published_display": "18 Apr 2026 02:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Announces 1-for-50 Reverse Stock Split Merger", "summary": "BioAtla announced a 1-for-50 reverse stock split through a merger with its wholly owned subsidiary, effective April 6, 2026. This move is intended to consolidate the share base and potentially impact trading dynamics, while preserving the company's existing corporate identity. An", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BCAB/pressreleases/1140124/bioatla-announces-1-for-50-reverse-stock-split-merger/", "source_name": "The Globe and Mail", "published_at": "2026-04-12T11:40:02", "published_display": "12 Apr 2026 11:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Announces Share Consolidation", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTFA5d1VGMFNzN2ExVG5oWTFrWGdsZGJLaGNGQXgxXzhxRVNmYWlOQUJxS1BOMTg3R05HNVZ0WE82M0g5cTV0TzNmRkhiOFdMVkVaRXNmYkxlWEowNlotZDFrTjZkRjg5QzFwZkFsWkt6VENjQQ?oc=5", "source_name": "Investing News Network", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla shrinks share count 50-for-1 to meet Nasdaq's $1 bid rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPRkVwbzJaT2Z3Q2dGbDl2MUU0U0RtcmhBZWNuNjFKS3Y4T2Z1YXlIOVdESUtRTlVvVE4tVTJqVVJKY3U2YS1qQXVMaTlUSUZyLWZpajZRVXB1U2o4SWFkN1VSM3QzNmNPVGw5RTYyN2NvOUw2N0JqOEJ6c0wtU0p4cmxfTVAzZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla announces 50-for-1 reverse stock split effective April 6", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdnVFWFo4N0J4R0t2SlhvdzROenVmWnV0V3ZQYktubF8xazdtWU1XaW1SbUFQenNhdDR0REVTOF82YXdnU1Y0QWxHNVpuUWdzY0tPbnJXc2dlYVJ4Q3NlOWlvTElER2MxcHBOVll6eHlzdk1ZYzNKRUxJbjVlcElFZUFjZWFXUGY5Z19WVkREMWxtZHhpekVmamFad2w4dmF1LW5BWVNETWZ3bnRyQzBnS1FOTlgtb1dmZ1Fz?oc=5", "source_name": "Investing.com", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotech BioAtla to shed 70% of staff while weighing asset sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOT1NnUjUxUVVGT2EzZExac3EzQmUyZ2luUEpjVGhNanBBZUxkZjRMSWNfTXE2QVdDQ3gyMmY1TnVEQmpmVzRjdUFPUUlzUHR2RlVyRHFOcUxiQUwwRk8zVzlObnJNUnhpUWFLMFdBMTNtUmFzcWVHMEw3RTJ0aW1iSWtZOTBMZEdBckxlR05NOFRoODhBbUR0M2Q0UHg1TjRPVG1GWmNFeTB4Xzk2end0a1FaZ3NBQS1BWU1odlhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNRHhpT2dIVXh1OFdsTGhYRjJTZHgyZ21fQmtBRUw2cV92SWlhdy0xLUlsd0lWMjRGeG13Yk94X1JDZ0RjQ09HdEVuNW5WYjZORkZEdzFXQ2ZoNGJXclNoT1A0OHBieG5hX0wwYkRQODkybms0Z1pXXzJVS0VFVDFiQjBUbURIbVVHaDlRWVcwUi1tWWR4Uzg4OUIzdk5DVzVpM2FQU0FUblV1V3RaY3l4ZVFlU244a2RVMnpiejlYcnVKOEFnaWtjWjNqU2d6clFsTEpPRmtHcw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla explores sale as it cuts 70% of workforce", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQWxld0dreXpqRk9GSHo5MzhxNzNfSG1PR1JHcXk2Z0hlQ1NLYV9MLVlUZ2lGdTdrWU5sQ2F6dkd4Xy01TE9KeVI5a2hHM2lQMHNabFBHX3FSUF8wWkh3c2dkVENhTG9wR29xSFpWZi1IWDJ0eDFuMzZqTXNFVklGSWplbzhGNGF0LTFPRVY3S1E2eElYSnE1VGt0cUc5U2o2WFNWMTJDV3g?oc=5", "source_name": "Investing.com", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Faces Nasdaq Delisting Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQR0kxeW40SEpRcXllLUNxakFseHZsaFRndS14OFlTRUdsSWVpLTVzbG5oUUM5M0xYdUtsV3J4bUp2Ykdac3NxVEloa0pfY1RHT1ptc0oyT0JmT2IwbHB6WW4xM3p5THE0YVFSNUhtV3dyY3h3OTFwSTYyTDVrdXNwUmx3VTFzcy1vazRpN3ZsOUU0M1ZwUjB3enNUMDlwc2s3?oc=5", "source_name": "TradingView", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla to be suspended from Nasdaq after delisting determination", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQZ3BwMDgyNkgtTk5MVUxLOElyQnYxcE1CM2ZpLWQzLU5SeW90Tlp5TzE4aXhIbEhDbS1DdjYzekJJU1llTUJVaHZYc3FneDJqZkphc2s5d240MGNzLVNXYS0yTFkzdV94dVA0MFNjX3M5QVdvWktiWUtmc3FsOE1Ma1pVd1hVdk1FSlRXSEdKMm1TblZ4dWtQTndkU1RGZHl2RGhway1URkw1YkJaOV9vMGZyS1pURjItNF9Id01n?oc=5", "source_name": "Investing.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla sets merger plan after Nasdaq rule change affects reverse split vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNUG5SWjR5enRSbHNkZXZnQ3dIaHdpSGNSUWZRbEJFY1JLRml6VjJ0OExQQUs5VmVJSUppMUZGWEllWUpYNXVvREFlU1hFbHdEV1QzT3RRWTM3eklKTXFBNFI3dE9tNXZHN0tfbENKbXBJT3lrb05TSkpUVmFEUmZVT1EyQ3NGS1lmZTZ6S1gtbWl6bXpaYjVrTTdtUmpheGcxUlhqb2wtZDBobTFkN3UwUmtGb3NETkI3YmpYTGZpeWJlaXhYQkd1NUZ5Sks?oc=5", "source_name": "Investing.com", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQN3MzVEQwd0M1WTlpMWtjSTVHOW1wUkk5Si1QWkZxZkdqNWdOTUw3RDlnT29NeXdrTFRVQnRaZ19uT0dJcEx0LWN3NkZIS2gwdThRdWE2WmI3US1reFdUcEhKZVJBc2t1eG1DOW5VN3Y4SG9XbGVTSnYtVHA3dWlJSnRyMFpDTWNlYTYtaVRIRXBkcVNEbFd2VUE0Rl9oY25E?oc=5", "source_name": "Investing News Network", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPOU5veEhQdTJ2OV9DSUpjWTV5Y19zdWpSUG9hY0NjaXNhTFNwcDJZYlVrUS1Uelkxb3dqTlh0aWtFa2tDN0NtXzVpbWxoTmM3NlU4R0lNQnJtempzTFRDN1pwbG9VaG13WDJHUFpDZXRhd1M3NVl2Qnp5Ylc2RUsxVkJ1NUl4NmttMzY2TDhvV0lxOURaT012YTMtbk91cDNGTmJ0UXN4eDZ3UWRWOTVz?oc=5", "source_name": "Investing News Network", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxNdVRFeGZIQS1XZ2dESjdkb2R3dE0xaWpfalZYb3FHaWJVUkxIQXQ1TV9ZV1k1RFozeHNmMzVUNENGTTNIY1NNSDZHUnJQbW9PUVRXRU9HQXF0bjN1dXVYTnNZc3dvVW9xNWlZa3FoMGJHenNxcnNBSHlIa3czUFR5bHNpbzRLem1hLVJTSDlJSDZvem1rQjUxWUlCZGVXWUdsdGhxaWZnemJ2c1paaU1uNjdkMFBSd2ZEV2QyWTEtaDV5VTBqVjFaR01xeTFkaFVVMldoS2tDdEVjQ09YaDg0eTZxU1FmcFo0UXdjVS03MmFiZ1dKTmdTbU5vVFhzc0MzRHVKSlZuMmRKWFBRdFB6ZzRFOTZHWk8wYXc2OWVQX0RqVnV4REVqaQ?oc=5", "source_name": "Investing News Network", "published_at": "2025-09-08T07:00:00+00:00", "published_display": "08 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-21T07:00:00+00:00", "published_display": "21 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (BCAB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE1wRzJJMG5lWFFSdmVUR2htODRLYkI0aGpWVndmaFZWOGgyMGVJNmQ3c2ZwZVUtUy16aUhpNWFFUWRTWlNOZUk3OThTS29zb2M?oc=5", "source_name": "Zacks Investment Research", "published_at": "2020-12-18T18:43:07+00:00", "published_display": "18 Dec 2020 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (BCAB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5KRXdCYUJ2X2tRUEVpVElXODJSdHc4NUs3N2VoYy1VaDlEQ2FWV3dVN1I0aEgyZldvSEdEZ2EwUDNHd2o0azZETUdrVl8xTUpMVFRSNEdJT0xxUQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-12-17T00:13:30+00:00", "published_display": "17 Dec 2020 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla (BCAB) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1iLU1BeFVSeG12bzFLczVsWFZJZjk3WHBNemV6ZmM0VU1LVy12ZnNfbDNkckdzcVFZcFhEV2NHSHl6ckdlUGRseS1ETzNQZw?oc=5", "source_name": "Stock Titan", "published_at": "2020-12-16T01:04:59+00:00", "published_display": "16 Dec 2020 01:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BioAtla: BioAtla, Inc. - Reverse Split Option Symbol: BCAB New Symbol: BCAB1", "summary": "This document announces that BioAtla, Inc. (BCAB) has undergone a reverse split, and a new option symbol, BCAB1, has been introduced. The article title and content solely focus on this corporate action.", "url": "https://www.moomoo.com/news/notice/306846774/bioatla-bioatla-inc-reverse-split-option-symbol-bcab-new-symbol", "source_name": "Moomoo", "published_at": "2026-06-27T22:41:09", "published_display": "27 Jun 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BioAtla, Inc. \u2013 NASDAQ:BCAB", "summary": "The article discusses the enterprise value to revenue forward for BioAtla, Inc. (NASDAQ: BCAB). It appears to be a financial listing or data point from a trading platform, providing a specific value for this financial metric during a particular period.", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T20:41:43", "published_display": "25 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB)", "summary": "This article provides an overview of BioAtla, Inc. (NASDAQ: BCAB) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers key metrics such as market capitalization, volatility, net income, and upcoming earnings dates, offering ", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:43", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Bioatla Inc (BCAB), highlighting its current valuation score of 9.98, which ranks 1st in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -0.02, significantly above its recent low. However, key P/B, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T06:11:35", "published_display": "23 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Bioatla Inc (BCAB), detailing its price momentum, support and resistance levels, and indicator and moving average signals. Currently, BCAB has a price momentum score of 7.42, trading between a resistance of $4.23 and support of $3.13,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/technical", "source_name": "TradingKey", "published_at": "2026-06-22T08:09:53", "published_display": "22 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE5nZ0pLY3FIc2NuSnEwOUluV0VmTjJ2WWR4b3dNaV9XT3FycmFjbUR0enFzRnBsd2poMTMzU2luSzZGZ1ZnZ2pIcWRaMW1QQlZJb2prcU5ZaHJuVUFWVkhtem03U2t1aGFValY2VGY1dWo?oc=5", "source_name": "TradingKey", "published_at": "2026-06-19T03:35:09+00:00", "published_display": "19 Jun 2026 03:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a revenue breakdown for Bioatla Inc (BCAB) but states that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows the stock's current trading status and market capitalization", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T03:11:37", "published_display": "19 Jun 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "The article provides an overview of Bioatla Inc.'s (BCAB) dividend and stock split history. It indicates that BCAB has not distributed any dividends over the past five years. However, it lists a significant stock split event planned as a 50-to-1 merger on March 31, 2026.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T02:11:37", "published_display": "19 Jun 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Bioatla Inc (BCAB) has an earnings forecast score of 10.00, placing it first in the Biotechnology & Medical Research industry. Analysts predict a strong buy trend with an average price target of $10.00, suggesting a significant upside. The company's recent EPS was -$8.18, with th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:05", "published_display": "18 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla | 4: Statement of changes in beneficial ownership of securities-Officer Sievers Eric", "summary": "This article is a statement of changes in beneficial ownership of securities for BioAtla, specifically concerning an officer named Sievers Eric. It is a regulatory filing indicating modifications in the individual's holdings of company securities.", "url": "https://www.moomoo.com/news/notice/307479501/bioatla-4-statement-of-changes-in-beneficial-ownership-of-securities", "source_name": "Moomoo", "published_at": "2026-06-10T03:09:13", "published_display": "10 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Inc. (BCAB) Q4 2025 Earnings: EPS Beat Driven by Lower Operating Loss, Stock Declines - Consensus Beat Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQQWNZc3BodWFsQVRxN3g5ZlRsdXZtZmdqcFRHRlFIOTlMYmlzZVZFMDd3MUtKMXpyVkRVa05HNkRsMWVaRzNhNVVfMnU3VVlsLV9kTm1YeW5JMGRJU3BZRTJRZ2lFOEtHdVpvQTE2UzRjYmdiZG1BMExkUThLem1DMEl0cFdHLTg4QjN5TGE5bDZjdFpWcGRFU3dsaENZLTJGdS1sMUFIWG52S3NDX3J1Y3JoS205SzZUeWdpdDFwSld3U1h2OGw3RmlJdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes", "summary": "BioAtla, Inc.'s Chief Medical Officer, Eric Sievers, had a total of 494 common shares withheld to cover income tax obligations related to vested restricted stock units. These transactions, occurring on March 11, 2026, and May 31, 2026, were tax-related share withholdings and not ", "url": "https://www.stocktitan.net/sec-filings/BCAB/form-4-bio-atla-inc-insider-trading-activity-058aabfa7c34.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:11:20", "published_display": "05 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (NASDAQ: BCAB) CEO reports routine tax-share withholdings after RSU vesting", "summary": "BioAtla, Inc. CEO Jay M. Short reported routine tax-related share dispositions following the vesting of restricted stock units (RSUs), not open-market sales. A total of 898 common shares were withheld by the company to cover income tax obligations across two dates in March and Ma", "url": "https://www.stocktitan.net/sec-filings/BCAB/form-4-bio-atla-inc-insider-trading-activity-6d41a4db30ee.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:11:19", "published_display": "05 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes", "summary": "BioAtla (NASDAQ: BCAB) Chief Financial Officer Christian Vasquez reported routine tax-withholding transactions concerning restricted stock units, not open-market stock sales. A total of 257 common shares were withheld by the company on two separate dates in 2026 to cover income t", "url": "https://www.stocktitan.net/sec-filings/BCAB/form-4-bio-atla-inc-insider-trading-activity-ded942ecae3f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:11:19", "published_display": "05 Jun 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla | DEFA14A: Others", "summary": "This article provides access to the DEFA14A document filed by BioAtla, which is a definitive additional soliciting material.", "url": "https://www.moomoo.com/news/notice/307460437/bioatla-defa14a-others", "source_name": "Moomoo", "published_at": "2026-06-04T15:39:47", "published_display": "04 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote", "summary": "BioAtla (NASDAQ: BCAB) has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held virtually. Shareholders will vote on the election of two Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and a non-binding advisory vo", "url": "https://www.stocktitan.net/sec-filings/BCAB/def-14a-bio-atla-inc-definitive-proxy-statement-1d2071416511.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:39:20", "published_display": "03 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCAB - BioAtla Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of BioAtla Inc. (BCAB) stock, including its latest stock price, financial metrics, analyst ratings, and recent news. It covers key financial data such as market cap, income, sales, and various ratios, alongside insider ownership and ins", "url": "https://finviz.com/stock?t=BCAB", "source_name": "Finviz", "published_at": "2026-06-01T09:10:09", "published_display": "01 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202", "summary": "Context Therapeutics has amended its exclusive license agreement with BioAtla for CT-202, eliminating future milestone and royalty obligations in exchange for an upfront payment of $4.5 million and a final payment of $2.0 million. This amendment grants Context Therapeutics full e", "url": "https://www.sahmcapital.com/news/content/context-therapeutics-enters-into-license-agreement-amendment-with-bioatla-for-ct-202-2026-05-18", "source_name": "Sahm", "published_at": "2026-05-20T03:10:23", "published_display": "20 May 2026 03:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal", "summary": "Context Therapeutics has gained full rights to CT-202 following a revised agreement with BioAtla. The article also briefly mentions Unity Software's Q4 financial results, including a 35% revenue increase year-over-year to $609 million and a quarterly loss of 66 cents per share.", "url": "https://www.moomoo.com/news/post/70178805/context-therapeutics-secures-full-rights-to-ct-202-under-revised?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-05-18T11:39:12", "published_display": "18 May 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context to pay $6.5M for full CT-202 rights by Aug. 1, 2026", "summary": "Context Therapeutics has amended its license agreement with BioAtla for CT-202, converting it into a fully paid-up, non-terminable license. This agreement eliminates all future CT-202 milestones and royalties for a total of $6.5 million, with $4.5 million upfront and a final $2.0", "url": "https://www.stocktitan.net/news/CNTX/context-therapeutics-enters-into-license-agreement-amendment-with-iw6ozf41iygo.html", "source_name": "Stock Titan", "published_at": "2026-05-18T11:10:08", "published_display": "18 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free", "summary": "Context Therapeutics has entered into an amendment with BioAtla to convert its antibody licenses, including CT-202, into irrevocable, royalty-free, fully paid-up, and non-terminable rights for $6.5 million. This agreement eliminates Context's R&D and reporting obligations, remove", "url": "https://www.tradingview.com/news/tradingview:63bc336a5abd5:0-context-therapeutics-pays-6-5-million-to-make-bioatla-antibody-licenses-perpetual-and-royalty-free/", "source_name": "TradingView", "published_at": "2026-05-18T11:10:08", "published_display": "18 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license", "summary": "Context Therapeutics (CNTX) has amended its license agreement with BioAtla for its CT-202 program, making the license royalty-free, fully paid-up, and non-terminable in exchange for upfront payments totaling $6.5 million. This agreement gives Context full economic rights to CT-20", "url": "https://www.stocktitan.net/sec-filings/CNTX/8-k-context-therapeutics-inc-reports-material-event-d61f0d627f0e.html", "source_name": "Stock Titan", "published_at": "2026-05-18T11:10:08", "published_display": "18 May 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of BioAtla, Inc. \u2013 NASDAQ:BCAB", "summary": "This article provides details on the number of shareholders for BioAtla, Inc. (NASDAQ: BCAB). It is presented on a TradingView page, indicating current market status and offering various financial tools and data. The core content focuses on shareholder figures, though the specifi", "url": "https://www.tradingview.com/symbols/NASDAQ-BCAB/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-05-14T17:40:13", "published_display": "14 May 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TradingKey", "summary": "This page provides an overview of Bioatla Inc (BCAB) stock performance, including its current price, market capitalization, and P/E TTM. The site offers various financial market data, news, analysis tools, and educational resources. It also includes sections for user comments and", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcab/comments", "source_name": "TradingKey", "published_at": "2026-05-11T14:39:52", "published_display": "11 May 2026 14:39", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (Nasdaq:BCAB) - Stock Analysis", "summary": "BioAtla (Nasdaq:BCAB) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancer. The company's stock has shown high volatility and significant decline over the past year, with ongoing concerns about cash burn, sharehold", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-bcab/bioatla", "source_name": "Simply Wall Street", "published_at": "2026-05-06T23:10:05", "published_display": "06 May 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive pay, board and share data detailed in BioAtla (NASDAQ: BCAB) 10-K/A", "summary": "BioAtla, Inc. filed an amended annual report (10-K/A) to include comprehensive details on executive compensation, board structure, and share ownership, which were previously omitted. The filing reflects a 50-for-1 share consolidation effective April 6, 2026, and provides updated ", "url": "https://www.stocktitan.net/sec-filings/BCAB/10-k-a-bio-atla-inc-amends-annual-report-df203fcc748e.html", "source_name": "Stock Titan", "published_at": "2026-04-29T20:40:23", "published_display": "29 Apr 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla to implement 50-for-1 share consolidation", "summary": "This article announces that BioAtla will implement a 50-for-1 share consolidation. The content details this corporate action.", "url": "https://www.msn.com/en-us/money/companies/bioatla-to-implement-50-for-1-share-consolidation/ar-AA1ZQHj2?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c", "source_name": "MSN", "published_at": "2026-04-25T02:39:43", "published_display": "25 Apr 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCAB Stock Chart | BIOATLA INC (NASDAQ:BCAB)", "summary": "This article provides a stock chart and real-time financial data for BIOATLA INC (NASDAQ:BCAB). It shows the current stock price, its daily change, and aftermarket activity. The page also lists various financial analysis tools and educational resources available on ChartMill.com.", "url": "https://www.chartmill.com/stock/quote/BCAB/stock-chart", "source_name": "ChartMill", "published_at": "2026-04-18T02:39:23", "published_display": "18 Apr 2026 02:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Announces 1-for-50 Reverse Stock Split Merger", "summary": "BioAtla announced a 1-for-50 reverse stock split through a merger with its wholly owned subsidiary, effective April 6, 2026. This move is intended to consolidate the share base and potentially impact trading dynamics, while preserving the company's existing corporate identity. An", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BCAB/pressreleases/1140124/bioatla-announces-1-for-50-reverse-stock-split-merger/", "source_name": "The Globe and Mail", "published_at": "2026-04-12T11:40:02", "published_display": "12 Apr 2026 11:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Announces Share Consolidation", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTFA5d1VGMFNzN2ExVG5oWTFrWGdsZGJLaGNGQXgxXzhxRVNmYWlOQUJxS1BOMTg3R05HNVZ0WE82M0g5cTV0TzNmRkhiOFdMVkVaRXNmYkxlWEowNlotZDFrTjZkRjg5QzFwZkFsWkt6VENjQQ?oc=5", "source_name": "Investing News Network", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla shrinks share count 50-for-1 to meet Nasdaq's $1 bid rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPRkVwbzJaT2Z3Q2dGbDl2MUU0U0RtcmhBZWNuNjFKS3Y4T2Z1YXlIOVdESUtRTlVvVE4tVTJqVVJKY3U2YS1qQXVMaTlUSUZyLWZpajZRVXB1U2o4SWFkN1VSM3QzNmNPVGw5RTYyN2NvOUw2N0JqOEJ6c0wtU0p4cmxfTVAzZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla announces 50-for-1 reverse stock split effective April 6", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPdnVFWFo4N0J4R0t2SlhvdzROenVmWnV0V3ZQYktubF8xazdtWU1XaW1SbUFQenNhdDR0REVTOF82YXdnU1Y0QWxHNVpuUWdzY0tPbnJXc2dlYVJ4Q3NlOWlvTElER2MxcHBOVll6eHlzdk1ZYzNKRUxJbjVlcElFZUFjZWFXUGY5Z19WVkREMWxtZHhpekVmamFad2w4dmF1LW5BWVNETWZ3bnRyQzBnS1FOTlgtb1dmZ1Fz?oc=5", "source_name": "Investing.com", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech BioAtla to shed 70% of staff while weighing asset sales", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOT1NnUjUxUVVGT2EzZExac3EzQmUyZ2luUEpjVGhNanBBZUxkZjRMSWNfTXE2QVdDQ3gyMmY1TnVEQmpmVzRjdUFPUUlzUHR2RlVyRHFOcUxiQUwwRk8zVzlObnJNUnhpUWFLMFdBMTNtUmFzcWVHMEw3RTJ0aW1iSWtZOTBMZEdBckxlR05NOFRoODhBbUR0M2Q0UHg1TjRPVG1GWmNFeTB4Xzk2end0a1FaZ3NBQS1BWU1odlhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla, Inc. Initiates Strategic Review Process and Workforce Restructuring to Enhance Shareholder Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNRHhpT2dIVXh1OFdsTGhYRjJTZHgyZ21fQmtBRUw2cV92SWlhdy0xLUlsd0lWMjRGeG13Yk94X1JDZ0RjQ09HdEVuNW5WYjZORkZEdzFXQ2ZoNGJXclNoT1A0OHBieG5hX0wwYkRQODkybms0Z1pXXzJVS0VFVDFiQjBUbURIbVVHaDlRWVcwUi1tWWR4Uzg4OUIzdk5DVzVpM2FQU0FUblV1V3RaY3l4ZVFlU244a2RVMnpiejlYcnVKOEFnaWtjWjNqU2d6clFsTEpPRmtHcw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla explores sale as it cuts 70% of workforce", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQQWxld0dreXpqRk9GSHo5MzhxNzNfSG1PR1JHcXk2Z0hlQ1NLYV9MLVlUZ2lGdTdrWU5sQ2F6dkd4Xy01TE9KeVI5a2hHM2lQMHNabFBHX3FSUF8wWkh3c2dkVENhTG9wR29xSFpWZi1IWDJ0eDFuMzZqTXNFVklGSWplbzhGNGF0LTFPRVY3S1E2eElYSnE1VGt0cUc5U2o2WFNWMTJDV3g?oc=5", "source_name": "Investing.com", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Faces Nasdaq Delisting Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQR0kxeW40SEpRcXllLUNxakFseHZsaFRndS14OFlTRUdsSWVpLTVzbG5oUUM5M0xYdUtsV3J4bUp2Ykdac3NxVEloa0pfY1RHT1ptc0oyT0JmT2IwbHB6WW4xM3p5THE0YVFSNUhtV3dyY3h3OTFwSTYyTDVrdXNwUmx3VTFzcy1vazRpN3ZsOUU0M1ZwUjB3enNUMDlwc2s3?oc=5", "source_name": "TradingView", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla to be suspended from Nasdaq after delisting determination", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQZ3BwMDgyNkgtTk5MVUxLOElyQnYxcE1CM2ZpLWQzLU5SeW90Tlp5TzE4aXhIbEhDbS1DdjYzekJJU1llTUJVaHZYc3FneDJqZkphc2s5d240MGNzLVNXYS0yTFkzdV94dVA0MFNjX3M5QVdvWktiWUtmc3FsOE1Ma1pVd1hVdk1FSlRXSEdKMm1TblZ4dWtQTndkU1RGZHl2RGhway1URkw1YkJaOV9vMGZyS1pURjItNF9Id01n?oc=5", "source_name": "Investing.com", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla sets merger plan after Nasdaq rule change affects reverse split vote", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNUG5SWjR5enRSbHNkZXZnQ3dIaHdpSGNSUWZRbEJFY1JLRml6VjJ0OExQQUs5VmVJSUppMUZGWEllWUpYNXVvREFlU1hFbHdEV1QzT3RRWTM3eklKTXFBNFI3dE9tNXZHN0tfbENKbXBJT3lrb05TSkpUVmFEUmZVT1EyQ3NGS1lmZTZ6S1gtbWl6bXpaYjVrTTdtUmpheGcxUlhqb2wtZDBobTFkN3UwUmtGb3NETkI3YmpYTGZpeWJlaXhYQkd1NUZ5Sks?oc=5", "source_name": "Investing.com", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQN3MzVEQwd0M1WTlpMWtjSTVHOW1wUkk5Si1QWkZxZkdqNWdOTUw3RDlnT29NeXdrTFRVQnRaZ19uT0dJcEx0LWN3NkZIS2gwdThRdWE2WmI3US1reFdUcEhKZVJBc2t1eG1DOW5VN3Y4SG9XbGVTSnYtVHA3dWlJSnRyMFpDTWNlYTYtaVRIRXBkcVNEbFd2VUE0Rl9oY25E?oc=5", "source_name": "Investing News Network", "published_at": "2025-11-20T08:00:00+00:00", "published_display": "20 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPOU5veEhQdTJ2OV9DSUpjWTV5Y19zdWpSUG9hY0NjaXNhTFNwcDJZYlVrUS1Uelkxb3dqTlh0aWtFa2tDN0NtXzVpbWxoTmM3NlU4R0lNQnJtempzTFRDN1pwbG9VaG13WDJHUFpDZXRhd1M3NVl2Qnp5Ylc2RUsxVkJ1NUl4NmttMzY2TDhvV0lxOURaT012YTMtbk91cDNGTmJ0UXN4eDZ3UWRWOTVz?oc=5", "source_name": "Investing News Network", "published_at": "2025-11-13T08:00:00+00:00", "published_display": "13 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma Following Productive Type B Meeting with FDA", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAJBVV95cUxNdVRFeGZIQS1XZ2dESjdkb2R3dE0xaWpfalZYb3FHaWJVUkxIQXQ1TV9ZV1k1RFozeHNmMzVUNENGTTNIY1NNSDZHUnJQbW9PUVRXRU9HQXF0bjN1dXVYTnNZc3dvVW9xNWlZa3FoMGJHenNxcnNBSHlIa3czUFR5bHNpbzRLem1hLVJTSDlJSDZvem1rQjUxWUlCZGVXWUdsdGhxaWZnemJ2c1paaU1uNjdkMFBSd2ZEV2QyWTEtaDV5VTBqVjFaR01xeTFkaFVVMldoS2tDdEVjQ09YaDg0eTZxU1FmcFo0UXdjVS03MmFiZ1dKTmdTbU5vVFhzc0MzRHVKSlZuMmRKWFBRdFB6ZzRFOTZHWk8wYXc2OWVQX0RqVnV4REVqaQ?oc=5", "source_name": "Investing News Network", "published_at": "2025-09-08T07:00:00+00:00", "published_display": "08 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-07-21T07:00:00+00:00", "published_display": "21 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (BCAB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE1wRzJJMG5lWFFSdmVUR2htODRLYkI0aGpWVndmaFZWOGgyMGVJNmQ3c2ZwZVUtUy16aUhpNWFFUWRTWlNOZUk3OThTS29zb2M?oc=5", "source_name": "Zacks Investment Research", "published_at": "2020-12-18T18:43:07+00:00", "published_display": "18 Dec 2020 18:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BioAtla (BCAB) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5KRXdCYUJ2X2tRUEVpVElXODJSdHc4NUs3N2VoYy1VaDlEQ2FWV3dVN1I0aEgyZldvSEdEZ2EwUDNHd2o0azZETUdrVl8xTUpMVFRSNEdJT0xxUQ?oc=5", "source_name": "MarketBeat", "published_at": "2020-12-17T00:13:30+00:00", "published_display": "17 Dec 2020 00:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bioatla (BCAB) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1iLU1BeFVSeG12bzFLczVsWFZJZjk3WHBNemV6ZmM0VU1LVy12ZnNfbDNkckdzcVFZcFhEV2NHSHl6ckdlUGRseS1ETzNQZw?oc=5", "source_name": "Stock Titan", "published_at": "2020-12-16T01:04:59+00:00", "published_display": "16 Dec 2020 01:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 53, "sentiment_summary": {"positive": 5, "negative": 6, "neutral": 42, "score": 50, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 16.3, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 3.82, "latest_week": "2026-07-10", "one_week_move": -8.8, "four_week_move": -1.0, "twelve_week_move": -16.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.143441, "market_dynamics_buy_signal": false, "relative_strength": -83.492682, "fair_value_gap": -93.6, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.0523, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.8% over one week, -1.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 10}, {"label": "TradingKey", "count": 7}, {"label": "TradingView", "count": 6}, {"label": "Market source", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "Investing News Network", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 2}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.8% over one week, -1.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BioAtla: BioAtla, Inc. - Reverse Split Option Symbol: BCAB New Symbol: BCAB1"}], "updated_at": "2026-07-16T05:42:04.181222+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}